| Tbio | Interleukin-12 receptor subunit beta-2 |
Receptor for interleukin-12. This subunit is the signaling component coupling to the JAK2/STAT4 pathway. Promotes the proliferation of T-cells as well as NK cells. Induces the promotion of T-cells towards the Th1 phenotype by strongly enhancing IFN-gamma production.
The protein encoded by this gene is a type I transmembrane protein identified as a subunit of the interleukin 12 receptor complex. The coexpression of this and IL12RB1 proteins was shown to lead to the formation of high-affinity IL12 binding sites and reconstitution of IL12 dependent signaling. The expression of this gene is up-regulated by interferon gamma in Th1 cells, and plays a role in Th1 cell differentiation. The up-regulation of this gene is found to be associated with a number of infectious diseases, such as Crohn's disease and leprosy, which is thought to contribute to the inflammatory response and host defense. Several transcript variants encoding different isoforms and non-protein coding transcripts have been found for this gene. [provided by RefSeq, Apr 2012]
The protein encoded by this gene is a type I transmembrane protein identified as a subunit of the interleukin 12 receptor complex. The coexpression of this and IL12RB1 proteins was shown to lead to the formation of high-affinity IL12 binding sites and reconstitution of IL12 dependent signaling. The expression of this gene is up-regulated by interferon gamma in Th1 cells, and plays a role in Th1 cell differentiation. The up-regulation of this gene is found to be associated with a number of infectious diseases, such as Crohn's disease and leprosy, which is thought to contribute to the inflammatory response and host defense. Several transcript variants encoding different isoforms and non-protein coding transcripts have been found for this gene. [provided by RefSeq, Apr 2012]
Comments
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Brain Injuries | 65 | 0.0 | 0.0 |
| Disease | Target Count | P-value |
|---|---|---|
| psoriasis | 6694 | 3.7e-10 |
| ependymoma | 4679 | 3.2e-08 |
| glioblastoma | 5792 | 3.9e-05 |
| atypical teratoid / rhabdoid tumor | 5112 | 6.8e-05 |
| medulloblastoma | 720 | 6.9e-04 |
| cystic fibrosis | 1696 | 1.1e-03 |
| Astrocytoma, Pilocytic | 3081 | 1.5e-03 |
| Atopic dermatitis | 952 | 2.3e-03 |
| pediatric high grade glioma | 1064 | 3.5e-03 |
| primitive neuroectodermal tumor | 3035 | 4.5e-03 |
| cutaneous lupus erythematosus | 1057 | 1.3e-02 |
| pulmonary arterial hypertension | 75 | 4.5e-02 |
| acute myeloid leukemia | 783 | 5.0e-02 |
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Primary biliary cirrhosis | 51 | 3.696 | 1.8 |
| Disease | log2 FC | p |
|---|---|---|
| acute myeloid leukemia | -2.300 | 5.0e-02 |
| Astrocytoma, Pilocytic | -1.200 | 1.5e-03 |
| Atopic dermatitis | 1.100 | 2.3e-03 |
| atypical teratoid / rhabdoid tumor | -1.500 | 6.8e-05 |
| cutaneous lupus erythematosus | 1.300 | 1.3e-02 |
| cystic fibrosis | 1.100 | 1.1e-03 |
| ependymoma | -1.200 | 3.2e-08 |
| glioblastoma | -1.100 | 3.9e-05 |
| medulloblastoma | -1.400 | 6.9e-04 |
| pediatric high grade glioma | -1.100 | 3.5e-03 |
| primitive neuroectodermal tumor | -1.700 | 4.5e-03 |
| psoriasis | 1.200 | 3.7e-10 |
| pulmonary arterial hypertension | -2.500 | 4.5e-02 |
| Species | Source | Disease |
|---|---|---|
| Inparanoid OMA EggNOG | ||
| Inparanoid OMA EggNOG | ||
| Inparanoid OMA EggNOG | ||
| Inparanoid OMA EggNOG | ||
| OMA EggNOG | ||
| Inparanoid OMA EggNOG | ||
| Inparanoid OMA EggNOG | ||
| Inparanoid OMA EggNOG | ||
| Inparanoid OMA EggNOG | ||
| Inparanoid OMA EggNOG | ||
| Inparanoid OMA EggNOG |
MAHTFRGCSLAFMFIITWLLIKAKIDACKRGDVTVKPSHVILLGSTVNITCSLKPRQGCFHYSRRNKLIL 1 - 70 YKFDRRINFHHGHSLNSQVTGLPLGTTLFVCKLACINSDEIQICGAEIFVGVAPEQPQNLSCIQKGEQGT 71 - 140 VACTWERGRDTHLYTEYTLQLSGPKNLTWQKQCKDIYCDYLDFGINLTPESPESNFTAKVTAVNSLGSSS 141 - 210 SLPSTFTFLDIVRPLPPWDIRIKFQKASVSRCTLYWRDEGLVLLNRLRYRPSNSRLWNMVNVTKAKGRHD 211 - 280 LLDLKPFTEYEFQISSKLHLYKGSWSDWSESLRAQTPEEEPTGMLDVWYMKRHIDYSRQQISLFWKNLSV 281 - 350 SEARGKILHYQVTLQELTGGKAMTQNITGHTSWTTVIPRTGNWAVAVSAANSKGSSLPTRINIMNLCEAG 351 - 420 LLAPRQVSANSEGMDNILVTWQPPRKDPSAVQEYVVEWRELHPGGDTQVPLNWLRSRPYNVSALISENIK 421 - 490 SYICYEIRVYALSGDQGGCSSILGNSKHKAPLSGPHINAITEEKGSILISWNSIPVQEQMGCLLHYRIYW 491 - 560 KERDSNSQPQLCEIPYRVSQNSHPINSLQPRVTYVLWMTALTAAGESSHGNEREFCLQGKANWMAFVAPS 561 - 630 ICIAIIMVGIFSTHYFQQKVFVLLAALRPQWCSREIPDPANSTCAKKYPIAEEKTQLPLDRLLIDWPTPE 631 - 700 DPEPLVISEVLHQVTPVFRHPPCSNWPQREKGIQGHQASEKDMMHSASSPPPPRALQAESRQLVDLYKVL 701 - 770 ESRGSDPKPENPACPWTVLPAGDLPTHDGYLPSNIDDLPSHEAPLADSLEELEPQHISLSVFPSSSLHPL 771 - 840 TFSCGDKLTLDQLKMRCDSLML 841 - 862 //
